0000000000790359

AUTHOR

Luis A. Balart

showing 1 related works from this author

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

2004

Multicenter randomized trials have shown that once-weekly pegylated interferon (peginterferon) alfa-2a is more efficacious than conventional interferon alfa-2a (IFN) in patients with chronic hepatitis C. We performed a meta-analysis of 1,013 previously untreated patients (from 3 randomized trials) with pretreatment and post-treatment liver biopsies to assess the differences between peginterferon alfa-2a and IFN in terms of their effects on liver histology. Reported values were standardized mean differences (SMD) between patients receiving peginterferon alfa-2a and those receiving IFN (post-treatment value minus baseline value for each group). We used a random-effects model to quantify the a…

Liver CirrhosisMaleCirrhosisFibrosiFemalGastroenterologyPolyethylene Glycolslaw.inventionRandomized controlled trialFibrosislawPegylated interferonChronicInterferon Alfa-2aInterferon Alfa-2bvirus diseasesHepatitis CMiddle AgedAdult; Antiviral Agents; Femal; Hepatitis C; Chronic; Humans; Interferon Alfa-2a; Interferon Alfa-2b; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Treatment Outcome; eHepatitis CRecombinant ProteinseTreatment OutcomeLiverPredictive value of testsFemalePeginterferon alfa-2amedicine.drugAdultmedicine.medical_specialtyEfficacypegylated interferon-alpha-2bBody-mass indexInterferon alpha-2Antiviral AgentsPredictive Value of TestsInternal medicinemedicineHumansInterferon-alpha therapySteatosiHepatologybusiness.industryInterferon-alphaHepatitis C ChronicHepatologymedicine.diseaseImmunologybusinessPredictor
researchProduct